Other meanings of High-throughput screening
Biotechnology
High-throughput screening (HTS) is a scientific method that enables the rapid testing of thousands to millions of chemical compounds, genetic constructs, or biological agents against specific biological targets, such as enzymes, receptors, or whole cells. It is a cornerstone of modern drug discovery, allowing researchers to identify potential lead compounds from vast libraries in a matter of days. HTS integrates automation, miniaturization, and advanced detection technologies to execute assays in parallel, often in 96-, 384-, or 1536-well microtiter plates. The approach has evolved from its origins in the 1980s to include ultra-high-throughput screening (uHTS) and phenotypic screening, expanding its applications beyond pharmaceuticals into areas like agrochemistry and chemical biology.
High-throughput screening relies on the parallel execution of biochemical or cell-based assays in miniature formats, typically using microtiter plates with 96, 384, or 1536 wells. The workflow begins with assay development, where a robust and reproducible test is designed to measure a specific biological activity, such as enzyme inhibition or receptor binding. Next, automated liquid handlers dispense compounds from libraries, often containing hundreds of thousands of small molecules, into the plates. After incubation, detection systems—such as fluorescence, luminescence, or absorbance readers—capture the signal from each well. The resulting data are processed using specialized software to identify 'hits'—compounds that show significant activity above a threshold, usually defined as a percentage of inhibition or activation. These hits are then validated through dose-response curves and counter-screens to eliminate false positives, a critical step given the inherent noise in high-density formats.
HTS is most prominently used in pharmaceutical research to identify lead compounds for therapeutic targets, such as kinases, G-protein-coupled receptors, and ion channels. For example, the discovery of the HIV protease inhibitor ritonavir involved HTS campaigns against the viral protease. Beyond small molecules, HTS has been adapted for RNA interference (RNAi) and CRISPR-based screens to probe gene function, enabling genome-wide loss-of-function studies. In academia, initiatives like the NIH Molecular Libraries Program have made HTS accessible for basic research, leading to the discovery of chemical probes for studying biological pathways. Additionally, HTS is applied in agrochemistry to screen for new pesticides and herbicides, and in industrial biotechnology to engineer enzymes with improved properties. The technique has also been used to identify compounds with potential antiviral activity, as seen in the rapid screening of existing drug libraries during the COVID-19 pandemic.
Advances in automation and detection have driven HTS from manual, low-throughput methods to ultra-high-throughput screening (uHTS) capable of screening over 100,000 compounds per day. Key innovations include acoustic droplet ejection for nanoliter dispensing, high-content screening (HCS) that combines automated microscopy with image analysis to capture cellular phenotypes, and label-free technologies like surface plasmon resonance. Miniaturization to 1536-well plates reduces reagent costs and sample volumes, but also increases the risk of evaporation and edge effects. Data quality is a major challenge, addressed through robust statistical metrics like the Z-factor, which assesses assay signal-to-noise ratio. Additionally, the 'hit-to-lead' process often suffers from high false-positive rates due to compound aggregation or interference, necessitating careful counter-screening. The integration of artificial intelligence and machine learning is now being explored to predict compound activity and optimize screening libraries, potentially reducing the need for exhaustive physical screening.
Beyond the mainstream narrative, HTS has several niche dimensions. One is the use of 'fragment-based screening', where low-molecular-weight fragments are screened at high concentrations to identify weak binders that are later elaborated into potent leads—a strategy that has yielded drugs like vemurafenib. Another is the application of HTS in 'chemical genetics', where small molecules are used to perturb biological systems to dissect pathways, a concept pioneered by researchers like Stuart Schreiber. In the realm of natural products, HTS has been adapted to screen microbial extracts, but the complexity of these mixtures often requires deconvolution, a challenge that has led to the development of 'high-throughput elicitor screening' to activate silent gene clusters in bacteria. Additionally, HTS has been used in environmental toxicology to assess the endocrine-disrupting potential of chemicals, as exemplified by the U.S. EPA's ToxCast program, which screens thousands of compounds across hundreds of assays. Finally, the 'frequent hitter' problem—where certain compounds appear as hits across many unrelated assays due to reactive groups—has prompted the development of 'pan-assay interference compounds' (PAINS) filters, a concept that has become standard in medicinal chemistry.
High-throughput screening has transformed biomedical research, but its success depends on careful assay design and data interpretation to avoid misleading results.
Help improve the encyclopedia. Reports go straight to the site manager.